美瑞健康国际(02327.HK)拟6274万港元出售德馨医药开发全部股份及股东贷款
格隆汇 11 月 20日丨美瑞健康国际(02327.HK)公告,于2020年11月20日,卖方瑞麻国际控股有限公司(公司直接全资附属公司)与买方宇城实业有限公司订立协议,据此,卖方同意出售而买方同意收购相当于目标公司德馨医药开发有限公司全部已发行股待售股份以及股东贷款,总代价为6274万港元。
目标公司主要从事买卖健康医疗产品、物业投资及租赁。于公告日期,目标公司拥有位于香港中环金钟道89号力宝中心1座29楼6室物业("该物业")。
公司主要从事投资控股。集团主要从事健康医疗相关业务、贸易业务、销售代理业务、物业投资及租赁业务以及物业发展业务。
考虑到集团现时财务状况及业务营运,董事认为出售事项乃公司以有利价格变现目标公司及该物业价值的良机,且出售事项的所得款项将改善集团的财务状况及增加一般营运资金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.